Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Janssen submits sNDA for Xarelto
Xarelto is an oral anticoagulant that reduces the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS). The drug candidate is also being assessed for
Xarelto is an oral anticoagulant that reduces the risk of (thrombotic) cardiovascular events in patients with Acute Coronary Syndrome (ACS). The drug candidate is also being assessed for
According to the company, MMJMenu provides business management software for dispensaries and growers, enabling them to track their medical cannabis from seed to sale. WeedMaps chief web officer
Following the amendment of the deal, UCB gains the flexibility to select a partner to sublicense its rights for certain territories. In addition, in return for the right
TRU-016 is a humanized anti-CD37 mono-specific protein therapeutic in development for the treatment of B-cell malignancies. Emergent will be entitled to a milestone payment of $6m with the
Levetiracetam, the generic version of UCB’s Keppra XR Tablets, is indicated as a treatment for partial onset seizures in patients over 16 years of age with epilepsy. Levetiracetam
Eprosartan Mesylate is the generic version of Abbott Laboratories’ Teveten Tablets, indicated for the treatment of hypertension. The company has been awarded 180 days of marketing exclusivity and
NSI-189 is the lead compound in Neuralstem’s neuroregenerative small molecule drug platform, indicated to treat psychiatric disorders such as Alzheimer’s disease, anxiety, bipolar disorder and post traumatic stress
Desloratadine, equivalent to Schering-Plough’s Clarinex tablets (5 mg), is indicated as a treatment for seasonal allergic rhinitis and perennial allergic rhinitis. Perrigo was sued for patent infringement based
The new ERP and customer relationship management system solution is expected to offer improved capabilities and efficiency for distribution. BDI SAP project manager Thomas Draughn said the company’s
Under the terms of the alliance, IGI Laboratories will develop and manufacture prescription topical drug products owned by Medimetriks Pharmaceuticals. Medimetriks has appointed IGI as Medimetriks’ authorized generic